AU2235992A - Transgenic immunodeficient non-human animals - Google Patents

Transgenic immunodeficient non-human animals

Info

Publication number
AU2235992A
AU2235992A AU22359/92A AU2235992A AU2235992A AU 2235992 A AU2235992 A AU 2235992A AU 22359/92 A AU22359/92 A AU 22359/92A AU 2235992 A AU2235992 A AU 2235992A AU 2235992 A AU2235992 A AU 2235992A
Authority
AU
Australia
Prior art keywords
human animals
immunodeficient non
transgenic immunodeficient
transgenic
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22359/92A
Inventor
Manley T. F Huang
Cornelis P Terhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genpharm International Inc
Original Assignee
Genpharm International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpharm International Inc filed Critical Genpharm International Inc
Publication of AU2235992A publication Critical patent/AU2235992A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU22359/92A 1991-06-14 1992-06-15 Transgenic immunodeficient non-human animals Abandoned AU2235992A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US716656 1985-03-27
US71665691A 1991-06-14 1991-06-14
US84131792A 1992-02-25 1992-02-25
US841317 1997-04-30

Publications (1)

Publication Number Publication Date
AU2235992A true AU2235992A (en) 1993-01-12

Family

ID=27109578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22359/92A Abandoned AU2235992A (en) 1991-06-14 1992-06-15 Transgenic immunodeficient non-human animals

Country Status (2)

Country Link
AU (1) AU2235992A (en)
WO (1) WO1992022645A1 (en)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
AU6760794A (en) 1993-05-26 1994-12-20 Ontario Cancer Institute, The Transgenic mammals lacking expression of particular cd45 isoforms
US5532158A (en) * 1994-10-21 1996-07-02 Ontario Cancer Institute Interleukin-2 receptor deficient mammals
ATE549918T1 (en) 1996-12-03 2012-04-15 Amgen Fremont Inc HUMAN ANTIBODIES THAT EXPRESSLY BIND HUMAN TNF ALPHA
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
TR200200735T2 (en) 1998-12-23 2002-06-21 Pfizer Inc. Human monoclonal antibodies for CTLA-4
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (en) 1999-08-24 2003-07-21 Medarex Inc Human ctla 4 antibodies and their uses.
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
ATE431406T1 (en) 2002-02-25 2009-05-15 Genentech Inc NEW TYPE 1 CYTOKINE RECEPTOR GLM-R
SI1503794T1 (en) 2002-04-12 2012-09-28 Medarex Inc Methods of treatement using ctla-4 antibodies
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
EP2316856B1 (en) 2002-10-17 2017-08-09 Genmab A/S Human monoclonal antibodies against CD20
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
AU2004224390A1 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
IN2012DN00313A (en) 2003-06-27 2015-05-08 Amgen Fremont Inc
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
JP2008507257A (en) 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Reduced risk of human anti-human antibodies through manipulation of V genes
KR100891620B1 (en) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 Anti-p-selectin antibodies
SI2287195T1 (en) 2004-07-01 2019-08-30 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN101389214A (en) 2004-10-22 2009-03-18 雷维维科公司 Ungulates with genetically modified immune systems
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
ATE492563T1 (en) 2004-11-17 2011-01-15 Amgen Inc COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
AU2005319404B2 (en) 2004-12-20 2011-10-20 Amgen Fremont Inc. Binding proteins specific for human Matriptase
PT1838733E (en) 2004-12-21 2011-12-13 Medimmune Ltd Antibodies directed to angiopoietin-2 and uses thereof
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
SI2567976T1 (en) 2005-03-23 2017-11-30 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US8110194B2 (en) 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
PL1979001T3 (en) 2005-12-13 2012-09-28 Medimmune Ltd Binding proteins specific for insulin-like growth factors and uses thereof
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
PL2463305T3 (en) 2006-01-12 2017-02-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
EP2010567A2 (en) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
ME03503B (en) 2006-09-26 2020-04-20 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
JP2010504955A (en) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム Bonding molecule adhesion molecule C (JAM-C) binding compound and method of use thereof
DK2125889T3 (en) 2007-02-21 2014-04-14 Univ Massachusetts HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND APPLICATIONS THEREOF
EP3524626A1 (en) 2007-03-22 2019-08-14 Biogen MA Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
US9322035B2 (en) 2007-05-31 2016-04-26 Genmab A/S Recombinant IgG4 monovalent antibodies
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
JP5624884B2 (en) 2007-08-02 2014-11-12 ノビミューンエスアー Anti-RANTES antibodies and methods of use thereof
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
MX2010003380A (en) 2007-09-26 2010-10-15 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins.
KR101811965B1 (en) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human dendritic and epithelial cell 205(dec-205)
RU2506276C2 (en) 2007-11-12 2014-02-10 УЗ ФАРМА ГмбХ Anti-axl antibodies
NZ600205A (en) 2008-01-25 2013-12-20 Univ Aarhus Selective exosite inhibition of papp-a activity against igfbp-4
JP5778577B2 (en) 2008-09-19 2015-09-16 メディミューン，エルエルシー Antibodies against DLL4 and uses thereof
KR101924874B1 (en) 2008-09-26 2018-12-04 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
EP2348827B1 (en) 2008-10-27 2015-07-01 Revivicor, Inc. Immunocompromised ungulates
HRP20230167T1 (en) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SG10201610247QA (en) 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
AR077594A1 (en) 2009-07-31 2011-09-07 Organon Nv COMPLETELY HUMAN ANTIBODIES FOR BTLA (ATTENUANT OF B AND T LYMPHOCYTES)
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JP5635617B2 (en) 2009-11-09 2014-12-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド Reagents and methods for detecting PNH type II leukocytes and their identification as risk factors for thrombotic disorders
EP2499159B1 (en) 2009-11-13 2017-01-04 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
ES2781299T3 (en) 2009-11-13 2020-09-01 Daiichi Sankyo Europe Gmbh Materials and methods to treat or prevent diseases associated with HER-3
PL2504364T3 (en) 2009-11-24 2017-12-29 Medimmune Limited Targeted binding agents against b7-h1
AU2011203879A1 (en) 2010-01-11 2012-08-02 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
CN105669865A (en) 2010-04-13 2016-06-15 塞尔德克斯医疗公司 Antibodies that bind human CD27 and uses thereof
RS65965B1 (en) 2010-04-20 2024-10-31 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
CN103153339B (en) 2010-05-27 2021-05-04 根马布股份公司 Monoclonal antibody directed against HER2 epitope
CN107253992B (en) 2010-05-27 2022-03-11 根马布股份公司 Monoclonal antibody against HER2
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
PL2582728T3 (en) 2010-06-15 2018-01-31 Genmab As Human antibody drug conjugates against tissue factor
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
EP2601220A2 (en) 2010-08-06 2013-06-12 U3 Pharma GmbH Use of her3 binding agents in prostate treatment
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
CN103619881B (en) 2011-04-07 2017-07-28 安姆根有限公司 New EGFR associated proteins
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
JP2014514314A (en) 2011-04-20 2014-06-19 ゲンマブ エー／エス Bispecific antibodies against HER2 and CD3
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
CN107903325B (en) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
JP6454547B2 (en) 2011-07-06 2019-01-16 ゲンマブ エー／エス Regulation of complement-dependent cytotoxicity by modification of the C-terminus of antibody heavy chain
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
WO2013067054A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
SG11201402365RA (en) 2011-11-16 2014-06-27 Amgen Inc Methods of treating epidermal growth factor deletion mutant viii related disorders
EP2812443B1 (en) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
US9453080B2 (en) 2012-06-11 2016-09-27 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
KR20240123420A (en) 2013-01-10 2024-08-13 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
ES2944477T3 (en) 2013-02-06 2023-06-21 Inhibrx Inc Non-Platelet Reducing and Non-Red Cell Reducing CD47 Antibodies and Methods of Using Them
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
DK2970449T3 (en) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh SINGLE-CHAINED BINDING MOLECULES COVERING N-TERMINAL ABP
JP6267792B2 (en) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド Methods for treating homozygous familial hypercholesterolemia
JP6617239B2 (en) 2013-08-14 2019-12-11 サイドゥ サチデーブ Antibodies against Frizzled protein and methods of use thereof
MX2016012873A (en) 2014-04-04 2017-03-07 Bionomics Inc Humanized antibodies that bind lgr5.
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
NZ728019A (en) 2014-07-11 2022-09-30 Genmab As Antibodies binding axl
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody constructs
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
JP2017531642A (en) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー Antibodies that bind to Ebola glycoprotein and uses thereof
KR102626877B1 (en) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof
NZ771169A (en) 2014-12-19 2024-07-26 Regenesance B V Antibodies that bind human c6 and uses thereof
TWI772258B (en) 2015-04-17 2022-08-01 德商安美基研究（慕尼黑）公司 Bispecific antibody constructs for cdh3 and cd3
CN108368171A (en) 2015-07-10 2018-08-03 根马布股份公司 AX L-specific antibody-drug conjugates for cancer therapy
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
TWI793062B (en) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
EP3334761B1 (en) 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
ES2935419T3 (en) 2016-02-03 2023-03-06 Amgen Res Munich Gmbh Bispecific antibody constructs for PSMA and CD3 that bind to T cells
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CA3016474A1 (en) 2016-03-15 2017-09-21 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
KR102414558B1 (en) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. Agonistic antibodies that bind to human CD40 and uses thereof
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
MX2019004371A (en) 2016-10-13 2019-11-18 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof.
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CN110072888B (en) 2016-12-16 2023-07-18 H.隆德贝克有限公司 Pharmaceutical agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018119380A2 (en) 2016-12-23 2018-06-28 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
US11918650B2 (en) 2017-05-05 2024-03-05 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR20200096814A (en) 2017-12-11 2020-08-13 암젠 인크 Continuous manufacturing process of bispecific antibody product
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
AU2019266203A1 (en) 2018-05-07 2020-11-26 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
EP3790584A4 (en) 2018-05-07 2022-03-30 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019313444A1 (en) 2018-07-30 2021-02-18 Amgen Inc. Prolonged administration of a bispecific antibody construct binding to CD33 and CD3
EA202190435A1 (en) 2018-08-03 2021-06-30 Эмджен Рисерч (Мюник) Гмбх ANTIBODY BASED CONSTRUCTIONS FOR CLDN18.2 AND CD3 BINDING
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
MX2021014644A (en) 2019-06-13 2022-04-06 Amgen Inc Automated biomass-based perfusion control in the manufacturing of biologics.
WO2021021676A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
CA3160151A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
EP4055051A1 (en) 2019-11-07 2022-09-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
AU2020409124A1 (en) 2019-12-20 2022-06-30 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
EP4077392A1 (en) 2019-12-20 2022-10-26 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021130383A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
JP2023518225A (en) 2020-03-19 2023-04-28 アムジエン・インコーポレーテツド Antibodies against mucin 17 and uses thereof
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
MX2022014902A (en) 2020-05-29 2023-01-04 Amgen Inc Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3.
CN116322787A (en) 2020-06-29 2023-06-23 展马博联合股份有限公司 Anti-tissue factor antibody-drug conjugates and their use in cancer treatment
JP2023540526A (en) 2020-09-04 2023-09-25 ノヴァロック バイオセラピューティクス， リミテッド Nectin-4 antibody and its use
CN116368154A (en) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 Trispecific binding agents
CR20230235A (en) 2020-11-06 2023-10-05 Amgen Res Munich Gmbh POLYPEPTIDE CONSTRUCTIONS THAT SELECTIVELY BIND CLDN6 AND CD3
US20240209078A1 (en) 2020-11-06 2024-06-27 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
CA3199931A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Polypeptide constructs binding to cd3
KR20230110274A (en) 2020-11-17 2023-07-21 씨젠 인크. Methods of treating cancer with a combination of tucatinib and an anti-PD-1/anti-PD-L1 antibody
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
JP2024529381A (en) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー Duplex Body
JP2024540017A (en) 2021-10-29 2024-10-31 シージェン インコーポレイテッド Methods of Treating Cancer Using a Combination of Anti-PD-1 Antibody and Anti-CD30 Antibody-Drug Conjugate
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
IL312515A (en) 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
TW202408583A (en) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with anti-tissue factor antibody-drug conjugates
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
TW202421650A (en) 2022-09-14 2024-06-01 美商安進公司 Bispecific molecule stabilizing composition
WO2024127366A1 (en) 2022-12-16 2024-06-20 Pheon Therapeutics Ltd Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504361A (en) * 1989-04-05 1992-08-06 ノバセル　コーポレイション Infectious targeted replication – defective virions
GB9100612D0 (en) * 1991-01-11 1991-02-27 Univ Edinburgh Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents

Also Published As

Publication number Publication date
WO1992022645A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
AU2235992A (en) Transgenic immunodeficient non-human animals
AU2384488A (en) Virus-resistant transgenic animals
EP0565189A3 (en) A construction for automatically milking animals
GB2267445B (en) Toys for cats
GB9307408D0 (en) Transgenic plants
AU5135693A (en) Transgenic animal models for neurodegenerative disease
EP0768027A3 (en) A Construction for automatically milking animals
GB2252709B (en) Bedding for animals
EP0692187A3 (en) An implement for milking animals
GB2261148B (en) An improved aquarium
GB9003966D0 (en) Improved dog kennel
PL300060A1 (en) Bait for animals
AU6904794A (en) Transgenic animals having an engineered immune response
IL99093A (en) Toy for farm animals
GB2263613B (en) Dog leash attachment
AU8735891A (en) B cell deficient transgenic non-human animals
GB9123314D0 (en) Transgenic animal production
AU2676692A (en) Transgenic plants
AU7466991A (en) Doubly transgenic animals
GB9503868D0 (en) Transgenic animals
AU1711792A (en) Improved dehorning means
GB9201315D0 (en) A feeder for young animals
HU911470D0 (en) Lure for rodents
AU3907895A (en) Transgenic non-human animals capable of producing heterologous antibodies
AU2003204055A1 (en) Transgenic non-human animals capable of producing heterologous antibodies